March 23, 2018 / 12:34 PM / 4 months ago

BRIEF-AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal

March 23 (Reuters) - Amag Pharmaceuticals Inc:

* AMAG PHARMACEUTICALS - ‍CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION​

* AMAG PHARMACEUTICALS - ‍SETTLEMENT DISMISSES & RESOLVES PATENT LITIGATION RELATED TO CO’S FERAHEME, 30 MG/ML, 17 ML SINGLE DOSE VIALS FOR INTRAVENOUS USE​

* AMAG PHARMACEUTICALS - ‍IF SANDOZ RECEIVES FDA APPROVAL BY A CERTAIN DATE, SANDOZ MAY LAUNCH GENERIC VERSION OF FERAHEME ON JULY 15, 2021, OR EARLIER​

* AMAG PHARMACEUTICALS - ‍SANDOZ TO PAY SALES ROYALTY OF GENERIC VERSION OF FERAHEME TO AMAG UNTIL EXPIRATION OF LAST FERAHEME PATENT LISTED IN ORANGE BOOK​ Source text for Eikon: (bit.ly/2DPHTEK) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below